{"id":958425,"date":"2026-05-05T17:11:13","date_gmt":"2026-05-05T21:11:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/"},"modified":"2026-05-05T17:11:13","modified_gmt":"2026-05-05T21:11:13","slug":"spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/","title":{"rendered":"Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., May  05, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C2o88yc237dX8DY3Giv-kM8DUX8oTiS_O75suGvVpRqlq7Gn9NkuWPAmIBtfZw7-mNExLZY88q6U1Fspo8_s-eHFsAwjPaYnp1dviCq56B4=\" rel=\"nofollow\" target=\"_blank\"><u>Spero Therapeutics<\/u><\/a>, Inc.\u00a0(Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the first quarter ended March 31, 2026, and provide a business update on Wednesday, May 13, 2026, after market close. The Company does not intend to host a conference call.<\/p>\n<p align=\"left\">\n        <strong>About Spero Therapeutics<\/strong><br \/>\n        <br \/>Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7RfvTmbR8yhqsvwUMMFzPyOl-v3VyGlBryr8i8UH6H5XznLefFpRvSXMJHVbNN1mLkW2MC0eUDp2y3ThSZ2mPknQp5nph5kE__Cvmu9ARoih3QJsihFO-65LYMsIzvrt\" rel=\"nofollow\" target=\"_blank\"><u>www.sperotherapeutics.com<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Shai Biran, PhD<br \/>Spero Therapeutics <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8jvTPgTYo0-sE6uF36mqC8UqGMcdaw1QswuBeznozugG1rliyEY8R-yWmwXGgjt8SuXGzItYclKvI5NLDTBZz5i3oojLy_khWcEQjqWDsTd21sQatSxXVnv9QMv2aDs2\" rel=\"nofollow\" target=\"_blank\"><u>IR@Sperotherapeutics.com<\/u><\/a><\/p>\n<p align=\"left\">\n        <strong>Media Inquiries:\u00a0<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2LNk5RgzX5U6mPckT243VMFAGlkG6bbApX0l7BkVrsd0m-CXl2Lme8VKROK0UG-oJOXhXOzinotxkroKM_2Ck-sxoqwnPO_OzKHS0zMw-4m0ChcdErF1ox4OWJo4kHeF\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>media@sperotherapeutics.com<\/u><br \/>\n        <\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjg2NCM3NTgyMDEwIzIwOTAzNjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWJjMDExNDQtYzEzNy00MmFhLThiMzAtNmFkNDBkMWQ2MGU2LTExMDE5MzMtMjAyNi0wNS0wNS1lbg==\/tiny\/Spero-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the first quarter ended March 31, 2026, and provide a business update on Wednesday, May 13, 2026, after market close. The Company does not intend to host a conference call. About Spero Therapeutics Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit www.sperotherapeutics.com. Investor Relations Contact: Shai Biran, PhDSpero Therapeutics IR@Sperotherapeutics.com Media Inquiries:\u00a0 media@sperotherapeutics.com<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-958425","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the first quarter ended March 31, 2026, and provide a business update on Wednesday, May 13, 2026, after market close. The Company does not intend to host a conference call. About Spero Therapeutics Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit www.sperotherapeutics.com. Investor Relations Contact: Shai Biran, PhDSpero Therapeutics IR@Sperotherapeutics.com Media Inquiries:\u00a0 media@sperotherapeutics.com\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-05T21:11:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjg2NCM3NTgyMDEwIzIwOTAzNjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026\",\"datePublished\":\"2026-05-05T21:11:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\\\/\"},\"wordCount\":133,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjg2NCM3NTgyMDEwIzIwOTAzNjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\\\/\",\"name\":\"Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjg2NCM3NTgyMDEwIzIwOTAzNjI=\",\"datePublished\":\"2026-05-05T21:11:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjg2NCM3NTgyMDEwIzIwOTAzNjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjg2NCM3NTgyMDEwIzIwOTAzNjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/","og_locale":"en_US","og_type":"article","og_title":"Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - Market Newsdesk","og_description":"CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) &#8212; Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the first quarter ended March 31, 2026, and provide a business update on Wednesday, May 13, 2026, after market close. The Company does not intend to host a conference call. About Spero Therapeutics Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit www.sperotherapeutics.com. Investor Relations Contact: Shai Biran, PhDSpero Therapeutics IR@Sperotherapeutics.com Media Inquiries:\u00a0 media@sperotherapeutics.com","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-05T21:11:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjg2NCM3NTgyMDEwIzIwOTAzNjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026","datePublished":"2026-05-05T21:11:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/"},"wordCount":133,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjg2NCM3NTgyMDEwIzIwOTAzNjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/","name":"Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjg2NCM3NTgyMDEwIzIwOTAzNjI=","datePublished":"2026-05-05T21:11:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjg2NCM3NTgyMDEwIzIwOTAzNjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjg2NCM3NTgyMDEwIzIwOTAzNjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=958425"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958425\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=958425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=958425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=958425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}